Syngene Presses Ahead With Capex And Capacity Build As Biologics Impact Weighs On Q3

Syngene International reported a softer December quarter after a large biologics programme weighed on revenue and margins, even as the company extended its strategic partnership with Bristol Myers Squibb through to 2035. Despite near-term pressure, the CRDMO has continued to invest in new facilities, advanced chemistry capabilities and technology platforms. In an interview with Business Today, Managing Director and CEO Peter Bains explains how Syngene is navigating current headwinds while staying committed to capital expenditure and long-term growth plans.